Amalgamated Bank’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-9,360
| Closed | -$133K | – | 2064 |
|
|
2025
Q4 | $133K | Buy |
9,360
+339
| +4% | +$3.33K | ﹤0.01% | 1659 |
|
|
2025
Q3 | $71K | Sell |
9,021
-1,203
| -12% | -$8.56K | ﹤0.01% | 1752 |
|
|
2025
Q2 | $59K | Hold |
10,224
| – | – | ﹤0.01% | 1797 |
|
|
2025
Q1 | $83K | Buy |
10,224
+35
| +0.3% | +$324 | ﹤0.01% | 1711 |
|
|
2024
Q4 | $96K | Hold |
10,189
| – | – | ﹤0.01% | 1710 |
|
|
2024
Q3 | $109K | Hold |
10,189
| – | – | ﹤0.01% | 1696 |
|
|
2024
Q2 | $101K | Buy |
10,189
+322
| +3% | +$3.31K | ﹤0.01% | 1708 |
|
|
2024
Q1 | $116K | Sell |
9,867
-30,418
| -76% | -$389K | ﹤0.01% | 1698 |
|
|
2023
Q4 | $572K | Sell |
40,285
-2,809
| -7% | -$31.9K | ﹤0.01% | 1394 |
|
|
2023
Q3 | $524K | Buy |
43,094
+602
| +1% | +$7.77K | ﹤0.01% | 1379 |
|
|
2023
Q2 | $534K | Buy |
42,492
+3,400
| +9% | +$40.3K | ﹤0.01% | 1405 |
|
|
2023
Q1 | $434K | Sell |
39,092
-6,426
| -14% | -$79.2K | ﹤0.01% | 1486 |
|
|
2022
Q4 | $556K | Buy |
45,518
+899
| +2% | +$10.1K | 0.01% | 1418 |
|
|
2022
Q3 | $466K | Buy |
44,619
+1,060
| +2% | +$11.8K | ﹤0.01% | 1470 |
|
|
2022
Q2 | $468K | Buy |
43,559
+511
| +1% | +$4.21K | ﹤0.01% | 1494 |
|
|
2022
Q1 | $408K | Sell |
43,048
-3,230
| -7% | -$30.3K | ﹤0.01% | 1639 |
|
|
2021
Q4 | $535K | Sell |
46,278
-502
| -1% | -$5.59K | ﹤0.01% | 1546 |
|
|
2021
Q3 | $447K | Sell |
46,780
-2,881
| -6% | -$29.5K | ﹤0.01% | 1640 |
|
|
2021
Q2 | $479K | Buy |
49,661
+13,052
| +36% | +$127K | ﹤0.01% | 1667 |
|
|
2021
Q1 | $362K | Sell |
36,609
-3,576
| -9% | -$55.4K | 0.01% | 1163 |
|
|
2020
Q4 | $928K | Buy |
40,185
+647
| +2% | +$13.2K | 0.04% | 587 |
|
|
2020
Q3 | $558K | Sell |
39,538
-1,159
| -3% | -$16.9K | 0.02% | 779 |
|
|
2020
Q2 | $614K | Sell |
40,697
-3,421
| -8% | -$41.7K | 0.03% | 704 |
|
|
2020
Q1 | $408K | Sell |
44,118
-1,388
| -3% | -$13.2K | 0.01% | 996 |
|
|
2019
Q4 | $443K | Buy |
45,506
+4,451
| +11% | +$40.7K | 0.01% | 1192 |
|
|
2019
Q3 | $329K | Sell |
41,055
-581
| -1% | -$6.31K | 0.01% | 1263 |
|
|
2019
Q2 | $520K | Buy |
41,636
+12,847
| +45% | +$163K | 0.01% | 1050 |
|
|
2019
Q1 | $392K | Buy |
28,789
+1,174
| +4% | +$14.3K | 0.01% | 1121 |
|
|
2018
Q4 | $265K | Buy |
27,615
+16,550
| +150% | +$182K | 0.01% | 1247 |
|
|
2018
Q3 | $134K | Sell |
11,065
-17,831
| -62% | -$249K | ﹤0.01% | 1374 |
|
|
2018
Q2 | $451K | Buy |
28,896
+4,011
| +16% | +$60.6K | 0.01% | 1089 |
|
|
2018
Q1 | $374K | Buy |
24,885
+2,119
| +9% | +$32.2K | 0.01% | 1104 |
|
|
2017
Q4 | $328K | Buy |
22,766
+1,749
| +8% | +$24K | 0.01% | 1218 |
|
|
2017
Q3 | $317K | Buy |
21,017
+2,566
| +14% | +$33.9K | 0.01% | 1179 |
|
|
2017
Q2 | $186K | Buy |
18,451
+1,002
| +6% | +$8.06K | 0.01% | 1458 |
|
|
2017
Q1 | $124K | Sell |
17,449
-30
| -0.2% | -$190 | 0.01% | 1433 |
|
|
2016
Q4 | $87K | Buy |
17,479
+2,661
| +18% | +$18.4K | ﹤0.01% | 1463 |
|
|
2016
Q3 | $110K | Buy |
14,818
+1,365
| +10% | +$9.22K | 0.01% | 1328 |
|
|
2016
Q2 | $90K | Buy |
13,453
+1,238
| +10% | +$8.66K | 0.01% | 1339 |
|
|
2016
Q1 | $103K | Buy |
12,215
+1,095
| +10% | +$7.75K | 0.01% | 1220 |
|
|
2015
Q4 | $108K | Sell |
11,120
-1,040
| -9% | -$9.37K | 0.01% | 1141 |
|
|
2015
Q3 | $170K | Buy |
+12,160
| New | +$191K | 0.02% | 1185 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Amalgamated Bank's FOLD Position: Q1 2026 in Review
Amalgamated Bank sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 9,360 shares — an estimated $133K sold.
Amalgamated Bank first reported a position in FOLD in Q3 2015 and held it in 42 quarters. The position peaked at $928K in Q4 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Amalgamated Bank reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
- Amalgamated Bank sold 9,360 Amicus Therapeutics shares in Q1 2026, an estimated $133K.
- Amalgamated Bank first reported a position in Amicus Therapeutics in Q3 2015 and held it in 42 quarters.
- Amalgamated Bank's Amicus Therapeutics position peaked at $928K in Q4 2020.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.